{"id":"anti-ip-10-antibody","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Injection site reaction"}]},"_chembl":{"chemblId":"CHEMBL2109418","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to IP-10, Anti-IP-10 Antibody reduces the recruitment of immune cells to sites of inflammation, which can help to reduce inflammation and potentially treat autoimmune diseases. This mechanism is thought to be beneficial in conditions such as psoriasis and multiple sclerosis.","oneSentence":"Anti-IP-10 Antibody works by binding to IP-10, a chemokine involved in the recruitment of immune cells to sites of inflammation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:10:03.737Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Psoriasis"}]},"trialDetails":[{"nctId":"NCT06737380","phase":"PHASE1","title":"UC-MSC Cell Therapy Study for Systemic Lupus Erythematosus (SLE) Patients","status":"RECRUITING","sponsor":"LiveKidney.Bio","startDate":"2025-01-07","conditions":"SLE, Lupus, Systemic Lupus Erthematosus","enrollment":10},{"nctId":"NCT05426577","phase":"","title":"Evaluation of Less Invasive Procedures for Visceral Leishmaniasis Treatment Efficacy Monitoring Test of Cure","status":"UNKNOWN","sponsor":"Foundation for Innovative New Diagnostics, Switzerland","startDate":"2021-09-01","conditions":"Visceral Leishmaniasis","enrollment":60},{"nctId":"NCT02864264","phase":"PHASE1","title":"Single Ascending Dose and Multiple Ascending Dose Study in Healthy Participants and Proof of Mechanism Study in Patients With Ulcerative Colitis","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2016-09-14","conditions":"Healthy Volunteers, Ulcerative Colitis","enrollment":7},{"nctId":"NCT00656890","phase":"PHASE2","title":"A Study of MDX-1100 in Subjects With Active Ulcerative Colitis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2008-04","conditions":"Ulcerative Colitis","enrollment":110},{"nctId":"NCT01466374","phase":"PHASE2","title":"Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-12","conditions":"Crohn's Disease","enrollment":121},{"nctId":"NCT01294410","phase":"PHASE2","title":"Induction and Maintenance Study of BMS-936557 Patients With Moderate to Severe Ulcerative Colitis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-03","conditions":"Colitis, Ulcerative","enrollment":305},{"nctId":"NCT01430429","phase":"PHASE2","title":"Primary Biliary Cirrhosis: Investigating A New Treatment Option Using NI-0801, an Anti-CXCL10 Monoclonal Antibody","status":"TERMINATED","sponsor":"Light Chain Bioscience - Novimmune SA","startDate":"","conditions":"Primary Biliary Cirrhosis","enrollment":""},{"nctId":"NCT01017367","phase":"PHASE2","title":"Study of MDX-1100 (Anti-CXCL10 Human Monoclonal Antibody) in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2008-02","conditions":"Rheumatoid Arthritis","enrollment":70},{"nctId":"NCT00295282","phase":"PHASE1","title":"A Dose-Escalation Study of MDX-1100 in Patients With Active Ulcerative Colitis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2006-01","conditions":"Ulcerative Colitis","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":15,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Anti-IP-10 Antibody","genericName":"Anti-IP-10 Antibody","companyName":"Bristol-Myers Squibb","companyId":"bristol-myers-squibb","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Anti-IP-10 Antibody works by binding to IP-10, a chemokine involved in the recruitment of immune cells to sites of inflammation. Used for Psoriasis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}